


## Supplemental Material

# DNA methylation changes during long-term *in vitro* cell culture are caused by epigenetic drift

Julia Franzen, Theodoros Georgomanolis, Anton Selich, Chao-Chung Kuo, Reinhard Stöger, Liliya Brant, Melita Sara Mulabdić, Eduardo Fernandez-Rebollo, Clara Grezella, Alina Ostrowska, Matthias Begemann, Miloš Nikolić, Björn Rath, Anthony D. Ho, Michael Rothe, Axel Schambach, Argyris Papantonis, Wolfgang Wagner


## Contents

Supplemental Figure S1: Growth curves and long-term culture-associated changes in cell preparations.....	2
Supplemental Figure S2: DNAm changes of different CpG subsets are reset at day 20 during reprogramming into iPSCs. ....	3
Supplemental Figure S3: Variations of DNAm patterns and estimation of Shannon index. ....	4
Supplemental Figure S4: Analysis of hairpin BBA-Seq.....	5
Supplemental Figure S5: Circular chromatin conformation capture in cis contacts.....	6
Supplemental Figure S6: Analysis of CTCF binding in early and late passage cells. ....	7
Supplemental Table S1. Illumina 450k BeadChip datasets. ....	8
Supplemental Table S2. Thirty selected long-term culture-associated CpGs.....	10
Supplemental Table S3. Pyrosequencing primers.....	11
Supplemental Table S4. Pyrosequencing results of training dataset.....	12
Supplemental Table S5. BBAseq primers.....	13
Supplemental Table S6. Hairpin linkers.....	14
Supplemental Table S7. Hairpin primers.....	14
Supplemental Table S8. 4C primers.....	15
Supplemental References.....	15




**Supplemental Figure S1: Growth curves and long-term culture-associated changes in cell preparations.**

**a)** Growth curves of the cell preparations of the training set (each dot represents a passage; cPD = cumulative population doublings). **b)** Representative images of senescence-associated beta galactosidase staining (AT = adipose-tissue-derived, BM = bone-marrow-derived, P = passage, size bar = 100  $\mu$ m). DNAm levels were measured by pyrosequencing in the training **(c)**, and validation set **(d)**. DNAm at all of the four long-term culture-associated CpGs correlated with passage numbers of cell preparations. **e)** Hydroxymethylation was analyzed with the TrueMethyl Array kit for three MSC donors in early (passage 4) and late (passage 10) passages. The plots depict hydroxymethylation (5hmC; %) at 646 hyper- and 2,442 hypomethylated culture-associated CpGs. Neither hyper- nor hypomethylated sites show high values of hydroxymethylation.




**Supplemental Figure S2: DNAm changes of different CpG subsets are reset at day 20 during reprogramming into iPSCs.**

DNAm levels at **a**) 9 CpGs of our epigenetic signatures <sup>1</sup>, **b**) 1,432 pluripotency associated CpG sites <sup>2</sup>, and **c**) 99 age-associated CpGs of our previously described age-predictor for blood samples <sup>3</sup> are depicted in MSCs of early (passage 2) and late passages (passage 7 to 16; GSE37067) <sup>4</sup>, during reprogramming of fibroblasts into iPSCs (GSE54848) <sup>5</sup>, and re-differentiation of iPSCs towards MSCs (iMSCs; GSE54767) <sup>6</sup>.




### Supplemental Figure S3: Variations of DNAm patterns and estimation of Shannon index.

**a)** Deep sequencing analysis of random barcodes demonstrates that MSCs of the second preparation become oligoclonal at later passages (in analogy to Figure 3a). **b)** Shannon index of RGB barcodes in the two UC-MSC donors and of the DNAm patterns in five different amplicons of the two donors. **c)** Frequencies of different DNAm patterns within neighboring CpGs for the second MSC preparation (in analogy to Figure 3c). **d)** Individual DNAm patterns are exemplarily depicted for 22 neighboring CpGs of *GRM7* of UC-MSC donor 2 (corresponding to Figure 3). The frequency of DNAm patterns resembles the percentage of corresponding reads in deep sequencing analysis. The height of each pattern corresponds to the frequency of this specific DNAm pattern, while the sum of all pattern frequencies adds up to 100%.



**Supplemental Figure S4: Analysis of hairpin BBA-Seq.**


**a)** Number of different unique molecular identifiers (UMIs) within hairpin loops detected for each amplicon. **b)** Passage predictions based on eight culture-associated CpGs either without or with consideration of different UMIs. **c)** Frequency of homo- and hemimethylation at culture-expansion-associated CpG sites that were used for predictions of passage numbers and at a highly methylated region (*C12orf12*). Grey colored regions resemble sequencing errors at one of the complementary CpG sites. One late passage donor of *CASR* is missing due to failed sequencing.



**Supplemental Figure S5: Circular chromatin conformation capture in cis contacts.**

**a)** Numbers of highly interacting regions called by 4Cker within nearbait (10 MB around the bait locus of interest) and cis contacts (same chromosome) of the four culture expansion associated CpGs. The histograms depict shared contacts of two donors for early passage and two donors for late passage, and they were similar at early and late passages. **b)** Numbers of significant differential contacts ( $p$ -value  $< 0.05$  by the FDR corrected 4Cker analysis) between early and late passages of all four regions in nearbait and cis contacts. **c)** Violin plots of the Pearson correlation of DNAm with passage numbers of all CpGs within the cis contacts of early passaged cells (light blue) or late passaged cells (dark blue) in comparison to all CpGs of the cis region (grey). Means are depicted by black bars and show that the subsets of CpGs within the highly interacting sites do not deviate from the overall mean of the cis region. **d)** In analogy to c) the violin plots depict the Pearson correlation for CpGs within the significantly differential contacts of the cis region in comparison to all CpGs of the cis region. **e)** Enrichment of lamina-associated domains (LADs) of a publicly available dataset of human fibroblasts<sup>7</sup> within high interacting sites of the four baits in cis compared to the mean interaction frequency of random background regions of the same size, which have been shuffled along the cis chromosome 1000 times. Significance was tested by Fisher's exact test (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; #  $p < 0.0001$ ).





**Supplemental Figure S6: Analysis of CTCF binding in early and late passage cells.**

**a)** Representative Integrative Genomics Viewer (IGV) overview of ChIP-seq peaks (chr5: 179221657 – 179230585; hg19, close to *LTC4S*) in early (P2, light blue) and late (P8 – P14, dark blue) passages. Peaks are associated to predicted CTCF motifs (violet lines at the bottom) and are reproducible in several donors, both in early and late passages as well as in a publicly available dataset (red, embryonic stem cell derived MSCs) <sup>8</sup>. **b)** Spearman correlation of normalized CTCF ChIP-seq peaks reveals high correlation for all samples irrespective of their passage number. **c, d)** Enrichment analysis of predicted motif binding sites for CTCF (c) and CTCFL (d) in high interacting regions of the 4C experiment. P-values were calculated with the RGT motif enrichment tool. Significant enrichment was particularly observed for the hypermethylated CpGs in *LTC4S* and *ALOX12*. **e)** Enrichment of CTCF ChIP-seq peaks within high interacting sites of the four baits in the 4C experiment compared to random background regions. To this end, CTCF binding peaks were further divided into early or late CTCF peaks, derived from corresponding early or late passaged samples respectively. Significance was tested by Fisher's exact test (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ).

**Supplemental Table S1. Illumina 450k BeadChip datasets.**

<b>Geo accession</b>	<b>GSE number</b>	<b>cell type</b>	<b>passage</b>	<b>Publication</b>
<b>GSM1004625</b>	GSE40927	fibroblast	4	Kurian, et al. <sup>9</sup>
<b>GSM1004626</b>	GSE40927	fibroblast	5	Kurian, et al. <sup>9</sup>
<b>GSM1004627</b>	GSE40927	fibroblast	14	Kurian, et al. <sup>9</sup>
<b>GSM1004643</b>	GSE40927	HUVEC	4	Kurian, et al. <sup>9</sup>
<b>GSM1004644</b>	GSE40927	HUVEC	4	Kurian, et al. <sup>9</sup>
<b>GSM1004645</b>	GSE40927	HUVEC	17	Kurian, et al. <sup>9</sup>
<b>GSM1027664</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027665</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027666</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027667</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027668</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027669</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027670</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027671</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027672</b>	GSE41933	MSC	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027673</b>	GSE41933	fibroblast	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027674</b>	GSE41933	fibroblast	2	Reinisch, et al. <sup>10</sup>
<b>GSM1027675</b>	GSE41933	fibroblast	2	Reinisch, et al. <sup>10</sup>
<b>GSM853409</b>	GSE37066	MSC	2	Koch, et al. <sup>4</sup>
<b>GSM853410</b>	GSE37066	MSC	2	Koch, et al. <sup>4</sup>
<b>GSM853411</b>	GSE37066	MSC	2	Koch, et al. <sup>4</sup>
<b>GSM853412</b>	GSE37066	MSC	2	Koch, et al. <sup>4</sup>
<b>GSM853413</b>	GSE37066	MSC	3	Koch, et al. <sup>4</sup>
<b>GSM909610</b>	GSE37066	MSC	7	Koch, et al. <sup>4</sup>
<b>GSM909612</b>	GSE37066	MSC	12	Koch, et al. <sup>4</sup>
<b>GSM909614</b>	GSE37066	MSC	16	Koch, et al. <sup>4</sup>
<b>GSM909616</b>	GSE37066	MSC	14	Koch, et al. <sup>4</sup>
<b>GSM909618</b>	GSE37066	MSC	14	Koch, et al. <sup>4</sup>
<b>GSM3230133</b>	GSE116375	MSC	4	this study
<b>GSM3230134</b>	GSE116375	MSC	4	this study
<b>GSM3230135</b>	GSE116375	MSC	4	this study
<b>GSM3230136</b>	GSE116375	MSC	10	this study
<b>GSM3230137</b>	GSE116375	MSC	10	this study
<b>GSM3230138</b>	GSE116375	MSC	10	this study
<b>GSM2340959</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340960</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340961</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340962</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340963</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340964</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340965</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340966</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340967</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340968</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM2340969</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>



<b>GSM2340970</b>	GSE87797	MSC	2	Fernandez-Rebollo, et al. <sup>11</sup>
<b>GSM1347975</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347978</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347981</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347984</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347987</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347989</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347991</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM1347993</b>	GSE55888	MSC	4	Schellenberg, et al. <sup>12</sup>
<b>GSM2186934</b>	GSE82234	HUVEC	4	Franzen, et al. <sup>13</sup>
<b>GSM2186935</b>	GSE82234	HUVEC	4	Franzen, et al. <sup>13</sup>
<b>GSM2186936</b>	GSE82234	HUVEC	4	Franzen, et al. <sup>13</sup>
<b>GSM3230129</b>	GSE116375	HUVEC	10	this study
<b>GSM3230130</b>	GSE116375	HUVEC	15	this study
<b>GSM3230131</b>	GSE116375	HUVEC	12	this study
<b>GSM3230132</b>	GSE116375	HUVEC	8	this study
<b>GSM2186937</b>	GSE82234	HUVEC	20	Franzen, et al. <sup>13</sup>
<b>GSM2186938</b>	GSE82234	HUVEC	18	Franzen, et al. <sup>13</sup>
<b>GSM2186939</b>	GSE82234	HUVEC	13	Franzen, et al. <sup>13</sup>

**Supplemental Table S2. Thirty selected long-term culture-associated CpGs**

<b>Illumina ID</b>	<b>Pearson (R)</b>	<b>R<sup>2</sup></b>	<b>Slope (m)</b>
cg25281820	-0.87786992	0.770655597	-0.02079236
cg03421657	-0.86871368	0.754663451	-0.02217539
cg21567022	-0.86815882	0.753699738	-0.03263046
cg10588720	-0.86669937	0.751167791	-0.02130874
cg16470423	-0.86548811	0.749069674	-0.02626191
cg23054188	-0.86328129	0.74525459	-0.02776338
cg05264232	-0.86248453	0.743879567	-0.02051906
cg07403610	-0.86147656	0.742141858	-0.024732
cg17625256	-0.8603098	0.740132952	-0.0238157
cg00063346	-0.85976139	0.73918965	-0.02255066
cg25968937	-0.85690853	0.734292227	-0.03551924
cg00791548	-0.85496971	0.730973203	-0.02079242
cg07566463	-0.85404073	0.729385561	-0.02079289
cg16819051	-0.85340441	0.728299093	-0.02279132
cg08732456	-0.85092846	0.724079248	-0.02796559
cg04682775	0.80592194	0.649510173	0.02106277
cg19443920	0.80854957	0.653752415	0.02610184
cg17180284	0.80937209	0.655083181	0.02006929
cg24628744	0.80950526	0.655298762	0.02028689
cg06221449	0.81021837	0.656453811	0.02305057
cg01815912	0.81744955	0.668223773	0.02761235
cg19759135	0.81834739	0.669692446	0.02261348
cg05054998	0.81942121	0.671451112	0.03632707
cg23602058	0.82959135	0.688221809	0.02256118
cg26683398	0.84259943	0.709973806	0.02118855
cg03762994	0.84439666	0.713005722	0.02743842
cg02717339	0.84612683	0.715930609	0.0210322
cg27456203	0.85926672	0.738339289	0.02156726
cg11394785	0.86553634	0.749153148	0.02060183
cg04065086	0.8684504	0.754206094	0.02188371

**Supplemental Table S3. Pyrosequencing primers**

<b>gene name</b>	<b>primer</b>	<b>Sequence 5' -&gt; 3'</b>
<b><i>ALOX12</i></b>	forward	GGGGTTATTTTTAATTTTTAAAGGAT
<b><i>ALOX12</i></b>	reverse	Biotin - AAAACACAACCAATCCCCACAA
<b><i>ALOX12</i></b>	sequencing	TTATTTTTAATTTTTAAAGGA
<b><i>DOK6</i></b>	forward	Biotin-ATGAGAAAATTGAGATATAATTTTATTTAGGAAATAG
<b><i>DOK6</i></b>	reverse	CACCTTTTCTTCTAAAATCTACAAATCCC
<b><i>DOK6</i></b>	sequencing	TCACACTCAAATCTAACCTA
<b><i>LTC4S</i></b>	forward	TTTTAGGGTTTTGTAGATTTTTATATTATGTTGGAGTTAG
<b><i>LTC4S</i></b>	reverse	Biotin - CACCCAAAAACCTTAAACAAATTTCC
<b><i>LTC4S</i></b>	sequencing	AATTTTTGTAAATTTTTTTTT
<b><i>TNNI3K</i></b>	forward	Biotin- ATTTTGTGGTTTTTTATAATGTTTTAGGAGTGTGATAA
<b><i>TNNI3K</i></b>	reverse	CCATAATCACTTTATTCACACTACATCACCAATACCCATTC
<b><i>TNNI3K</i></b>	sequencing	CAATAAAATACCTAACATAATACT

**Supplemental Table S4. Pyrosequencing results of training dataset**

<b>Sample</b>	<b><i>ALOX12</i></b>	<b><i>DOK6</i></b>	<b><i>LTC4S</i></b>	<b><i>TNNI3K</i></b>	<b>Real passage</b>	<b>Predicted passage</b>
<b>AT MSC 1</b>	0.04	0.88	0.23	0.95	1	3
<b>AT MSC 1</b>	0.09	0.66	0.48	0.84	8	8
<b>AT MSC 1</b>	0.18	0.61	0.62	0.64	15	16
<b>AT MSC 2</b>	0.04	0.86	0.23	0.97	1	2
<b>AT MSC 2</b>	0.09	0.59	0.56	0.85	10	8
<b>AT MSC 2</b>	0.42	0.48	0.63	0.66	18	12
<b>AT MSC 3</b>	0.02	0.88	0.17	0.96	1	2
<b>AT MSC 3</b>	0.05	0.61	0.39	0.89	7	6
<b>AT MSC 3</b>	0.12	0.35	0.58	0.63	14	16
<b>Fibroblast</b>	0.06	0.78	0.33	0.9	2	5
<b>Fibroblast</b>	0.16	0.47	0.51	0.77	10	10
<b>Fibroblast</b>	0.34	0.66	0.66	0.83	17	7
<b>Fibroblast</b>	0.04	0.85	0.3	0.92	3	4
<b>Fibroblast</b>	0.2	0.85	0.59	0.32	37	28
<b>Fibroblast</b>	0.03	0.88	0.23	0.94	3	3
<b>Fibroblast</b>	0.15	0.84	0.48	0.66	15	14
<b>Fibroblast</b>	0.21	0.83	0.8	0.44	30	24
<b>Fibroblast</b>	0	0.85	0.21	0.92	3	4
<b>Fibroblast</b>	0.05	0.63	0.33	0.58	20	18
<b>HUVEC 1</b>	0.13	0.73	0.37	0.94	1	3
<b>HUVEC 1</b>	0.36	0.53	0.91	0.68	8	14
<b>HUVEC 1</b>	0.61	0.51	0.67	0.64	14	11
<b>HUVEC 2</b>	0.13	0.81	0.22	0.94	1	2
<b>HUVEC 2</b>	0.32	0.68	0.67	0.87	6	5
<b>HUVEC 2</b>	0.46	0.63	0.71	0.7	10	11
<b>HUVEC 3</b>	0.08	0.81	0.21	0.95	1	2
<b>HUVEC 3</b>	0.33	0.75	0.7	0.84	7	7
<b>HUVEC 3</b>	0.42	0.64	0.83	0.71	12	11
<b>HUVEC 3</b>	0.55	0.57	0.94	0.29	21	27
<b>HUVEC 4</b>	0.11	0.84	0.18	0.95	1	2
<b>HUVEC 4</b>	0.35	0.68	0.73	0.86	7	6
<b>HUVEC 4</b>	0.53	0.76	0.9	0.64	13	13
<b>HUVEC 4</b>	0.61	0.76	0.91	0.22	21	29
<b>BM MSC 1</b>	0.08	0.66	0.31	0.93	2	4
<b>BM MSC 1</b>	0.11	0.47	0.41	0.93	7	4
<b>BM MSC 2</b>	0.04	0.66	0.25	0.94	2	3
<b>BM MSC 2</b>	0.08	0.44	0.34	0.87	7	6
<b>BM MSC 2</b>	0.13	0.63	0.36	0.75	13	10
<b>BM MSC 3</b>	0.08	0.69	0.35	0.93	2	4
<b>BM MSC 3</b>	0.08	0.63	0.4	0.81	6	9
<b>BM MSC 3</b>	0.09	0.62	0.56	0.62	11	17
<b>BM MSC 2</b>	0.1	0.68	0.37	0.88	7	6
<b>BM MSC 3</b>	0.08	0.47	0.38	0.89	5	6
<b>BM MSC 1</b>	0.11	0.53	0.34	0.92	4	4

Methylation values of single CpGs are depicted as  $\beta$ -values ranging from 0 to 1.

**Supplemental Table S5. BBAseq primers**

<b>gene name</b>	<b>primer</b>	<b>Sequence 5' -&gt; 3'</b>
<b><i>ALOX12</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTGGGGTATTTTTAATTTTAAAGGAT
<b><i>ALOX12</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTAAAACACAACCAATCCCCACAA
<b><i>DOK6</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTATGAGAAAATTGAGATATAATTTTATTTAGGAAATAG
<b><i>DOK6</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCACCTTTTCTTCTAAAATCTACAAATCCC
<b><i>LTC4S</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTTTTAGGGTTTTGTAGATTTTATATTATGTTGGAGTTAG
<b><i>LTC4S</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCACCCAAAAACCTTAAACAAATTTCC
<b><i>TNNI3K</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTATTTTGTGGTTTTTTATAATGTTTTAGGAGTGTGATAA
<b><i>TNNI3K</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCCATAATCACTTTATTCACTACATCACCAATACCCATTC
<b><i>GRM7</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTTTGGGATTATTGTTGATTT
<b><i>GRM7</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCCCCTACTACCTACTAAAATA
<b><i>CASR</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTTGTAATAGGTATTTGGTTGTAGT
<b><i>CASR</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCCCAAACCTTACTCATTCTA
<b><i>PRAMEF2</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTTTTGAGGGTATTTAGAAGAGAT
<b><i>PRAMEF2</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTAACTAACTACTAATC
<b><i>SELP</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTAGAAGGTAGAAAATTAGTAGAGTT
<b><i>SELP</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCAACATAAAACTCCATAACTA
<b><i>CASP14</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTTTGGAGATTTAGTGAGATAATA
<b><i>CASP14</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTAACAAAACAAATAACCCATATA
<b><i>KRTAP13.3</i></b>	forward	CTCTTTCCCTACACGACGCTCTTCCGATCTGAGATTTGTTGGAGGTTTAA
<b><i>KRTAP13.3</i></b>	reverse	CTGGAGTTCAGACGTGTGCTCTTCCGATCTCCAATAAAAAACAACCTCC

**Supplemental Table S6. Hairpin linkers**

<b>Name</b>	<b>Sequence 5' -&gt; 3'</b>	<b>CpG sites [enzyme]</b>
<b>Hairpin-1</b>	Phosphate-CTAGCGATGCDDDDDDDDGCATCGCT	<i>CASR</i> [AccI]
<b>Hairpin-2</b>	Phosphate-TAAGCGATGCDDDDDDDDGCATCGCT	<i>SELP, PRAMEF2, GRM7, GNAS, DOK6</i> [CviQI]
<b>Hairpin-3</b>	Phosphate-TGAAGCGATGCDDDDDDDDGCATCGCT	<i>KRTAP13.3</i> [DdeI]
<b>Hairpin-4</b>	Phosphate-AGAGCGATGCDDDDDDDDGCATCGCT	<i>C12orf12, TNNI3K</i> [AccI]
<b>Hairpin-5</b>	Phosphate-TTAAGCGATGCDDDDDDDDGCATCGCT	<i>LTC4S</i> [DdeI]

Hairpin linkers were designed with different overhangs, which are complementary to the sticky ends of the restriction digest at each CpG site with respective enzymes indicated in square brackets. Unique molecular identifiers (UMIs) consisted of random A,G and T nucleotides represented by the letter D.

**Supplemental Table S7. Hairpin primers**

<b>Primer name</b>	<b>Sequence 5' -&gt; 3'</b>
<b>HPnewCASR forw</b>	GTTTAAATTTTTATTTATTTTGTAAGATTTAGG
<b>HPnewCASR rev</b>	ACTCTTACTCATTCTACAAAACCTC
<b>HPnewGRM7 forw</b>	GAGTAGTATGGTTTAGTTGAGG
<b>HPnewGRM7 rev</b>	CATAATCCAATAAAAAAACTACTCC
<b>HPnewKRTAP13.3 forw</b>	GTAATTTTTGTTTGATTATGTATGTTGG
<b>HPnewKRTAP13.3 rev</b>	ATATTAATCCAACCCCTACCAC
<b>HPnewPRAMEF2 forw</b>	GGTTGGTTGTTGATTAGATGGG
<b>HPnewPRAMEF2 rev</b>	CTAACTACTAATCAAATAAACATAACCC
<b>HPnewSELP forw</b>	TAGGTAAAGGTTTAGAAAGTGAGG
<b>HPnewSELP rev</b>	TAAACAAAAACAAAAACCAACAAAATCAC
<b>HPnewDOK6 forw</b>	TTAAAGAGATATAATAAAAAATAGGTGGG
<b>HPnewDOK6 rev</b>	CAAAAACTACTTAAAATACCTATTTTAC
<b>HPnewLTC4S forw</b>	GTTTTTTGTTTTATTTAGGTTGTTTTTGG
<b>HPnewLTC4S rev</b>	ATCCAAACTATTCCTAACAACCC
<b>HPnewTNNI3K forw</b>	GTATTATTAGTATTTATTTTATAGTAGAGTG
<b>HPnewTNNI3K rev</b>	ATCACTACATCACCAATACCC
<b>HPnewGNAS forw</b>	ATTTTTTTTTTTTTGTTTAGAGAGG
<b>HPnewGNAS rev</b>	CATCCCTTCTTCTTACTC
<b>HPnewC12orf12 forw</b>	AGTTTTAGTTTTATTTAGTATATTTGGG
<b>HPnewC12orf12 rev</b>	AATCCCAACCAACACACCT

**Supplemental Table S8. 4C primers**

<b>Viewpoint</b>	<b>primer</b>	<b>sequence</b>
<b>ALOX12</b>	forward	ATCCAGTAAGGGACAGACAC
<b>ALOX12</b>	reverse	GTAATATCCAAATAAAATGGCTC
<b>LTC4S</b>	forward	GGGTCCTCCCATGGAGAATT
<b>LTC4S</b>	reverse	GAGCACCATGAAGAACTTTGC
<b>KRTAP13.3</b>	forward	CACACACCATTGAAATGACAG
<b>KRTAP13.3</b>	reverse	CTCTGCAATTCTTGCCTGAC
<b>CASR</b>	forward	AGACCGTGACCTTGGCATAG
<b>CASR</b>	reverse	ATGCAGTATTCCACCCTTGC

**Supplemental References**

- 1 Koch, C. M. *et al.* Monitoring of cellular senescence by DNA-methylation at specific CpG sites. *Aging cell* **11**, 366-369, doi:10.1111/j.1474-9726.2011.00784.x (2012).
- 2 Nazor, K. L. *et al.* Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. *Cell stem cell* **10**, 620-634, doi:10.1016/j.stem.2012.02.013 (2012).
- 3 Weidner, C. I. *et al.* Aging of blood can be tracked by DNA methylation changes at just three CpG sites. *Genome Biology* **15**, R24-R24, doi:10.1186/gb-2014-15-2-r24 (2014).
- 4 Koch, C. M. *et al.* Pluripotent stem cells escape from senescence-associated DNA methylation changes. *Genome research* **23**, 248-259, doi:10.1101/gr.141945.112 (2013).
- 5 Olova, N., Simpson, D. J., Marioni, R. E. & Chandra, T. Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity. *Aging cell* **18**, e12877, doi:10.1111/accel.12877 (2019).
- 6 Frobel, J. *et al.* Epigenetic Rejuvenation of Mesenchymal Stromal Cells Derived from Induced Pluripotent Stem Cells. *Stem Cell Reports* **3**, 414-422, doi:10.1016/j.stemcr.2014.07.003 (2014).
- 7 Guelen, L. *et al.* Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. *Nature* **453**, 948-951, doi:nature06947 [pii];10.1038/nature06947 [doi] (2008).
- 8 Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331-336, doi:10.1038/nature14222 (2015).
- 9 Kurian, L. *et al.* Conversion of human fibroblasts to angioblast-like progenitor cells. *Nat Methods* **10**, 77-83, doi:10.1038/nmeth.2255 (2013).
- 10 Reinisch, A. *et al.* Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. *Blood* **125**, 249-260, doi:10.1182/blood-2014-04-572255 (2015).
- 11 Fernandez-Rebollo, E. *et al.* Human Platelet Lysate versus Fetal Calf Serum: These Supplements Do Not Select for Different Mesenchymal Stromal Cells. *Scientific Reports* **7**, 5132, doi:10.1038/s41598-017-05207-1 (2017).
- 12 Schellenberg, A. *et al.* Matrix elasticity, replicative senescence and DNA methylation patterns of mesenchymal stem cells. *Biomaterials* **35**, 6351-6358, doi:S0142-9612(14)00477-3 [pii];10.1016/j.biomaterials.2014.04.079 [doi] (2014).
- 13 Franzen, J. *et al.* Senescence-associated DNA methylation is stochastically acquired in subpopulations of mesenchymal stem cells. *Aging cell* **16**, 183-191, doi:10.1111/accel.12544 (2017).